Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Select Medical Holdings (SEM) Long-Term Investments (2016 - 2023)

Historic Long-Term Investments for Select Medical Holdings (SEM) over the last 10 years, with Q2 2023 value amounting to $18.4 million.

  • Select Medical Holdings' Long-Term Investments changed N/A to $18.4 million in Q2 2023 from the same period last year, while for Jun 2023 it was $18.4 million, marking a year-over-year change of. This contributed to the annual value of $45.2 million for FY2022, which is 15034.62% up from last year.
  • Per Select Medical Holdings' latest filing, its Long-Term Investments stood at $18.4 million for Q2 2023.
  • In the past 5 years, Select Medical Holdings' Long-Term Investments ranged from a high of $45.2 million in Q4 2022 and a low of $18.1 million during Q4 2021
  • In the last 3 years, Select Medical Holdings' Long-Term Investments had a median value of $22.7 million in 2023 and averaged $27.2 million.
  • Data for Select Medical Holdings' Long-Term Investments shows a peak YoY increase of 15034.62% (in 2022) and a maximum YoY decrease of 15034.62% (in 2022) over the last 5 years.
  • Over the past 3 years, Select Medical Holdings' Long-Term Investments (Quarter) stood at $18.1 million in 2021, then surged by 150.35% to $45.2 million in 2022, then plummeted by 59.3% to $18.4 million in 2023.
  • Its Long-Term Investments stands at $18.4 million for Q2 2023, versus $27.0 million for Q1 2023 and $45.2 million for Q4 2022.